# CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma

> **NCT07383233** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Qi deng** · enrollment: 18 (estimated)

## Conditions studied

- Lymphoma
- CAR T Cell Therapy
- Acute Leukemia

## Interventions

- **BIOLOGICAL:** CD19/BAFF-R in vivo CAR-T cell intravenous infusion

## Key facts

- **NCT ID:** NCT07383233
- **Lead sponsor:** Qi deng
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07383233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07383233, "CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07383233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*